Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Molecular changes in the joint fluid during surgical joint distraction reveal markers that may drive cartilage repair in osteoarthritis.

Knee with osteoarthritis © Shutterstock
Changes found in the knee joint fluid during surgical joint distraction may explain cartilage repair

It is generally accepted that cartilage is not able to heal or regenerate itself after injury or through wear and tear, leading to the development of osteoarthritis. But there is a body of evidence emerging that challenges this view.

Recent studies show evidence of cartilage regeneration following a surgical procedure called joint distraction. A research team from the Centre for Osteoarthritis Pathogenesis, Versus Arthritis within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) set out, in collaboration with partners in the Netherlands, to investigate whether there were molecular changes within the environment of the knee joint that could explain the repair.

The team studied a group of 20 individuals with osteoarthritis undergoing knee joint distraction, an intervention that uses an external frame fixed to both sides of the joint to gradually pull apart the knee by 5mm over 6 weeks. A benefit of the treatment, which is not yet offered in the UK, is that it takes pressure off the joint while enabling the patient to continue to walk on the leg. Knee joint distraction has previously been shown in clinical studies by the Netherlands group not only to lead to sustained improvements in knee symptoms but also to repair cartilage as measured by magnetic resonance imaging.

"It's something that goes against the dogma because people think that once the cartilage is gone that's it," said Fiona Watt, Associate Professor at NDORMS. "We were interested to know whether this intervention was changing the joint environment to promote cartilage regrowth, and if we could measure markers which might represent repair pathways. Identifying such pathways might help us to develop new treatments to prevent or delay knee arthroplasty or to treat osteoarthritis in other joints in the future, as well as understanding how this particular intervention brings about benefit."

A small sample of joint fluid was taken from each patient when the knee distraction frame was fitted, at the mid-point of distraction, and at six weeks, the point at which the distractor was removed. Patients were followed for a year in total and their osteoarthritis symptoms assessed. The team looked for changes in a panel of ten markers, previously identified as important in the response to joint injury and in repair, to determine whether any changes in the fluid could be linked to response to intervention and clinical improvement.

Change in TGFß during distractionChange in TGFß during distraction

"Several markers changed with distraction, but two markers, FGF2 and TGFß, showed a significant increase in the joint during distraction and predicted a good clinical outcome," said Professor Tonia Vincent, Director of the Centre for OA Pathogenesis at NDORMS. "Both of these are growth factors that are associated with cartilage repair in laboratory studies. Although ours was a small exploratory study, it shows that the biology in the joint changes rapidly when mechanical stress is altered and this likely facilitates cartilage repair. Identifying the molecules that drive the intrinsic power of cartilage to repair may help us to identify new molecular treatments for osteoarthritis.

 

Change in FGF-2 during distractionChange in FGF-2 during distraction

Caroline Aylott, Head of Research Delivery at Versus Arthritis says, “This work by our Centre for Osteoarthritis Pathogenesis is important in helping us to understand the biological processes at work when the body is trying to repair damage to cartilage. By understanding the chemical signals involved, we may, in the future be able to develop treatments to help repair cartilage and reduce the need for joint replacements.”

Published in Osteoarthritis Research Society International, the study was supported by Versus Arthritis, ReumaNederlands, the Dutch Arthritis Society, and by the NIHR Oxford Biomedical Research Centre (BRC).

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.